Glaxosmithkline Regulatory News (GSK)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Luke Miels

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

232

£21.6700

630

£21.6700

316

d)

Aggregated information

Aggregated volume Price

1,178

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

458

£21.6700

589

£21.6700

506

d)

Aggregated information

Aggregated volume Price

1,553

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

132

£21.6700

132

£21.6700

334

d)

Aggregated information

Aggregated volume Price

598

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

109

£21.6700

339

£21.6700

205

d)

Aggregated information

Aggregated volume Price

653

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 9 April 2026 on ADSs held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.3600

53

$58.3600

96

$58.3600

159

d)

Aggregated information

Aggregated volume Price

308

$58.3600

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

David Redfern

b)

Position/status

President, Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

161

£21.6700

401

£21.6700

183

d)

Aggregated information

Aggregated volume Price

745

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

169

£21.6700

483

£21.6700

268

d)

Aggregated information

Aggregated volume Price

920

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

117

£21.6700

163

£21.6700

270

d)

Aggregated information

Aggregated volume Price

550

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

154

£21.6700

418

£21.6700

252

d)

Aggregated information

Aggregated volume Price

824

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 April 2026 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£21.6700

215

£21.6700

235

£21.6700

515

d)

Aggregated information

Aggregated volume Price

965

£21.6700

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Elizabeth McKee Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.9307

26

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Charles Bancroft

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.9307

313

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.9307

26

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Anne Beal

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.9307

32

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Harry Dietz

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.9307

30

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Jeannie Lee

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.9307

14

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vishal Sikka

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.9307

96

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-09

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$59.1703

270.573

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Maya Martinez-Davis

b)

Position/status

President, US

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

​

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$59.1703

292.894

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Maya Martinez-Davis

b)

Position/status

President, US

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

​

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.3600

151.897

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

​

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 9 April 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$59.1703

600.819

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-14

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Diana Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

​

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS under GSK pension plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$58.3499

11.357

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-04-13

f)

Place of the transaction

New York Stock Exchange (XNYS)